Acurx shares surge 18.83% intraday on Zacks upgraded Buy rating and 22.7% higher earnings estimate revisions.

Acurx Pharmaceuticals (ACXP) surged 18.83% intraday, driven by a Zacks Rank upgrade to #2 (Buy) and a 22.7% rise in full-year earnings estimates over 90 days, signaling improved analyst sentiment. The stock outperformed its medical sector peers, which gained 5.4% year-to-date, while ACXP returned 14.9%. The positive earnings outlook and strong relative performance likely fueled the intraday rally, aligning with the Zacks model’s emphasis on earnings revisions as a key indicator of near-term outperformance.